The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

Nvidia-backed AI drug developer Iambic raises $150m in IPO

October 16

Iambic said it will use the proceeds to advance three early-stage cancer drug candidates.

Chips & compute Funding & deals

Read at Tech in Asia ↗

One letter a week, starting soon.

Latest

Nvidia-backed AI drug developer Iambic raises $150m in IPO

Related

ValleyMueon nabs $65M in funding to develop 3D computing modules SiliconANGLE

SiliconVolvo Cars and NVIDIA Expand Partnership to Advance Safe Automated Driving NVIDIA Newsroom

AsiaByteDance nears deal to buy MediaTek’s custom AI chips for data centers TechNode

EuropeSalience Labs secures $125M to scale photonic chips for AI data centres Tech.eu

AsiaChina chip exports jump 136% to US$45b as AI frenzy jacks up prices SCMP Tech

AsiaAI inference-chip startup SUNMMIO completes Pre-A2 and Series A funding TechNode